Cell Reset: siRNA for Transcription Factors
TRANSCRIPTIONAL DAMAGE
Diseases that reduce human lifespan are linked to widespread transcriptional dysregulation.
Transcription factors are intrigugin drug targets, but historically were viewed as “too complex” and “undruggable.”
BREAKTHROUGH SCIENCE
Junevity founders at UCSF were the first to show that repression of a single transcription factor can rejuvenate gene expression in a human cell model of aging.
JUNEVITY RESET PLATFORM
The RESET Platform is the first to use human omics data, machine learning, and siRNA to unlock transcription factors for longevity-related diseases.
This approach offers a path to safe, effective therapeutics to reset the health of our tissues, one disease at a time.
THERAPEUTICS DEVELOPMENT
Junevity is pioneering first-in-class siRNA therapeutics to treat diseases impacting billions of people worldwide.
The first programs are in Type 2 Diabetes, Obesity, CNS, Osteoarthritis, and Sarcopenia.
We imagine a world with longer, healthier lives for all.